124 related articles for article (PubMed ID: 38677771)
1. Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells
Solis-Estrada J; Arredondo-Espinoza E; Pioquinto-Ávila E; González-Cruz AO; Zarate X; Balderas-Rentería I
Anticancer Res; 2024 May; 44(5):1955-1962. PubMed ID: 38677771
[TBL] [Abstract][Full Text] [Related]
2. Design, expression and evaluation of a novel humanized single chain antibody against epidermal growth factor receptor (EGFR).
Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Rahbarnia L
Protein Expr Purif; 2016 Nov; 127():8-15. PubMed ID: 27298212
[TBL] [Abstract][Full Text] [Related]
3. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A.
Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Barzegar A; Rahbarnia L
Anticancer Drugs; 2017 Mar; 28(3):263-270. PubMed ID: 27861173
[TBL] [Abstract][Full Text] [Related]
4. Development and Evaluation of a Cetuximab-based Humanized Single Chain Antibody Against EGFR-overexpressing Tumors.
Veisi K; Farajnia S; Zarghami N; Khorshid HR; Samadi N; Safdari Y; Ahmadzadeh V
Drug Res (Stuttg); 2015 Dec; 65(12):624-8. PubMed ID: 25333654
[TBL] [Abstract][Full Text] [Related]
5. Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing.
Forsyth CM; Juan V; Akamatsu Y; DuBridge RB; Doan M; Ivanov AV; Ma Z; Polakoff D; Razo J; Wilson K; Powers DB
MAbs; 2013; 5(4):523-32. PubMed ID: 23765106
[TBL] [Abstract][Full Text] [Related]
6. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
[TBL] [Abstract][Full Text] [Related]
7. Design, expression and characterization of a single chain anti-CD20 antibody; a germline humanized antibody derived from Rituximab.
Ahmadzadeh V; Farajnia S; Hosseinpour Feizi MA; Khavarinejad RA
Protein Expr Purif; 2014 Oct; 102():45-51. PubMed ID: 25088934
[TBL] [Abstract][Full Text] [Related]
8. Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells.
Banisadr A; Safdari Y; Kianmehr A; Pourafshar M
Hum Vaccin Immunother; 2018 Apr; 14(4):856-863. PubMed ID: 29185855
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
11. Humanization by CDR grafting and specificity-determining residue grafting.
Kim JH; Hong HJ
Methods Mol Biol; 2012; 907():237-45. PubMed ID: 22907355
[TBL] [Abstract][Full Text] [Related]
12. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
Kang HN; Kim SH; Yun MR; Kim HR; Lim SM; Kim MS; Hong KW; Kim SM; Kim H; Pyo KH; Park HJ; Han JY; Youn HA; Chang KH; Cho BC
Lung Cancer; 2016 May; 95():57-64. PubMed ID: 27040853
[TBL] [Abstract][Full Text] [Related]
13. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
[TBL] [Abstract][Full Text] [Related]
14. Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.
Chang KH; Kim MS; Hong GW; Shin YN; Kim SH
Exp Mol Med; 2012 Jan; 44(1):52-9. PubMed ID: 22064379
[TBL] [Abstract][Full Text] [Related]
15. Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.
Yi CH; Ruan CP; Wang H; Xu XY; Zhao YP; Fang M; Ji J; Gu X; Gao CF
Acta Pharmacol Sin; 2014 Nov; 35(11):1439-46. PubMed ID: 25263334
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
[TBL] [Abstract][Full Text] [Related]
17. Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy.
Nakanishi T; Maru T; Tahara K; Sanada H; Umetsu M; Asano R; Kumagai I
Protein Eng Des Sel; 2013 Feb; 26(2):113-22. PubMed ID: 23118340
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
[TBL] [Abstract][Full Text] [Related]
19. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
[TBL] [Abstract][Full Text] [Related]
20. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
